Related Experiment Video
Updated: Apr 13, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
[Re-appraisal of risk assessment schemes in gastrointestinal stromal tumors]
1Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China. caohuishcn@hotmail.com.
Abstract:
The biological behavior of gastrointestinal stromal tumor(GIST) is highly variable. To assess the risk of recurrence of the primary tumor accurately is a key challenge. The risk assessment system of GIST has experienced several revolutions. The present accepted risk stratification scheme is still to be consummated. The pathological morphological characteristics, mutational features, and other biomarkers are helpful to improve the risk assessment system. The risk assessment of GIST in the future will be more and more diversified.

